Clinical trials: Nonalcoholic Steatohepatitis
Nonalcoholic Steatohepatitis
Study of SGM-1019 in Patients With Nonalcoholic Steatohepatitis (NASH)
This is a multicenter, randomized, double-blind, placebo-controlled study evaluating the safety, pharmacokinetics, and pharmacodynamics of 12 weeks' administration of SGM-1019 in subjects with fibrosis stage 1-3 (F1-F3) NASH.
- Trial name
- NCT03676231
- Testing
- SGM-1019
- Where
- 10 sites in United States
- Volunteers
- 9 people
- Sponsor
- Second Genome
Metabolic Dysfunction-Associated Steatotic Liver Disease, Nonalcoholic Fatty Liver
Effect of a GnRH Analog on Hepatic Steatosis
Menopause increases the risk of metabolic dysfunction-associated steatotic liver disease (MASLD), possibly owing to the abrupt lack of estrogen.
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease, Nonalcoholic Fatty Liver, Endometriosis
- Trial name
- EndomMASLD (NCT06523530)
- Testing
- Goserelin Acetate 3.6 mg inj, implant
- Where
- 2 sites in Greece
- Volunteers
- 62 people
- Sponsor
- Aristotle University Of Thessaloniki
Fatty Liver
Limonene on Regulating Metabolism-related Fatty Liver Disease (MAFLD) and Analysis of TCM Constitution
The prevention and treatment of metabolic-related fatty liver disease (MAFLD) involves many fields in preventive medicine and clinical medicine.
- Trial name
- DL-MAFLD-TCM (NCT04853082)
- Testing
- Limonene capsule
- Where
- China
- Volunteers
- 57 people
- Sponsor
- Hongsheng Tan
MASLD, MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease)
Accurate Point of Care Liver Disease Diagnostics (Phase 2)
This research study is being conducted to find out more about techniques to non-invasively evaluate liver disease. This is the second phase of a project in which we are testing a new technology to evaluate the liver…
- Conditions
- MASLD, MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease), NAFLD, NAFLD (Nonalcoholic Fatty Liver Disease)
- Trial name
- NCT07518784
- Testing
- LiverScope® exam, MR exam, Blood draw
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- University of California, San Diego
Overweight and Obesity, Non-alcoholic Fatty Liver Disease
Nonalcoholic Fatty Liver Disease and Atherosclerotic Risk in Children
Nonalcoholic fatty liver disease is a serious health condition in overweight children which can lead to heart disease. This project will examine the links between liver health and cardiovascular risk factors in overweight and…
- Trial name
- SMART (NCT02383485)
- Testing
- Exercise, After-school program
- Where
- United States
- Volunteers
- 175 people, healthy volunteers welcome
- Sponsor
- Augusta University
Intermittent Fasting, Metabolic Dysfunction-Associated Fatty Liver Disease
Intermittent Fasting and Metabolic Dysfunction Associated Fatty Liver Disease
Previous studies have investigated the effect of different dietary patterns on metabolic dysfunction-associated fatty liver disease (MAFLD), for which lifestyle modification remains the primary treatment.
- Trial name
- NCT06664684
- Testing
- Energy-restricted dietary intervention, Energy + time-restricted dietary intervention
- Where
- Turkey (Türkiye)
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Istanbul Bilgi University
NAFLD, Nonalcoholic Fatty Liver
The Impact of Ibutamoren on Nonalcoholic Fatty Liver Disease
Nonalcoholic fatty liver disease (NAFLD), fatty infiltration of the liver in the absence of alcohol use, is an increasingly recognized complication of obesity, with prevalence estimates of about 30% of individuals in the United…
- Conditions
- NAFLD, Nonalcoholic Fatty Liver, NASH - Nonalcoholic Steatohepatitis
- Trial name
- NCT05364684
- Testing
- LUM-201
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
NAFLD, MASLD
Determination of Biological Activity of Enriched Serum Following TOTUM-448 Consumption
Dietary intakes of saturated fatty acids remain well above nutritional recommendations for most European countries. This may progressively lead to a pro-inflammatory context and the alteration of lipid metabolism in the liver.
- Conditions
- NAFLD, MASLD, Mild Inflammatory Context
- Trial name
- CnC-TOTUM448 (NCT06047847)
- Testing
- TOTUM-448
- Where
- France
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Valbiotis
Non-Alcoholic Steatohepatitis
A Sub-study of BMS-986036 in Subjects With Non-Alcoholic Steatohepatitis (NASH)
The purpose of this sub-study of MB130-045 is to determine the pharmacokinetic effects, pharmacodynamic effects, efficacy and safety of BMS-986036 20 mg QD in subjects with Non-alcoholic Steatohepatitis (NASH)
- Trial name
- NCT03400163
- Testing
- BMS-986036
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- Bristol-Myers Squibb
NASH - Nonalcoholic Steatohepatitis
Safety and Tolerability of HepaStem in Patients With Cirrhotic and Pre-cirrhotic NASH Patients
Multicenter, open-label, safety and tolerability study of ascending doses of HepaStem in patients with cirrhotic and pre-cirrhotic non-alcoholic steato-hepatitis (NASH) to determine the safety and tolerability of ascending single…
- Trial name
- PANASH (NCT03963921)
- Testing
- HepaStem
- Where
- 13 sites in Belgium, Bulgaria and 2 more
- Volunteers
- 23 people
- Sponsor
- Cellaion SA
Cardiovascular Diseases, Metabolic Syndrome
Redirecting Immune, Lipid and Metabolic Drivers of Early Cardiovascular Disease: The RESET Cohort Study
Project RESET is a Singapore National Medical Research Council Large Collaborative Grant funded program that brings together a nationwide community of cardiovascular, metabolic, and digital health researchers, as well as…
- Conditions
- Cardiovascular Diseases, Metabolic Syndrome, Non-Alcoholic Fatty Liver Disease
- Trial name
- RESET (NCT06211868)
- Testing
- Digital wearable and AI-human symbiotic lifestyle intervention
- Where
- Singapore
- Volunteers
- 3,000 people
- Sponsor
- National University Hospital, Singapore
T2DM, MAFLD
The Effect of Alogliptin Combined With Actoplus Met on Glucose and Lipid Metabolism and Pancreatic Function in Patients With T2DM Complicated With MAFLD
To compare the efficacy and safety of the combination of alogliptin and actoplus met with that of actoplus met alone in improving the glucose and lipid metabolism and pancreatic function in T2DM patients complicated with MAFLD.
- Trial name
- NCT07289750
- Testing
- alogliptin and actoplus met, actoplus met
- Volunteers
- 80 people
- Sponsor
- The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Inflammatory Bowel Disease (IBD), Metabolic Dysfunction Associated Fatty Liver Disease
An Observational Study of Inflammatory Bowel Disease (IBD) Patients With Non-alcoholic Fatty Liver Disease (NAFLD)
Inflammatory bowel diseases (IBD), including ulcerative colitis and Crohn's disease, are currently of unknown etiology and incurable.
- Trial name
- NCT06939569
- Where
- China
- Volunteers
- 337 people
- Sponsor
- Shanghai East Hospital
Nonalcoholic Fatty Liver
A Study of the Efficacy and Safety of PXL770 Versus Placebo After 12 Weeks of Treatment in Patients With NAFLD
This study will assess the efficacy and safety of 3 doses of PXL770 versus placebo after 12 weeks of treatment.
- Trial name
- NCT03763877
- Testing
- PXL770
- Where
- 15 sites in United States
- Volunteers
- 121 people
- Sponsor
- Poxel SA
Metabolic Dysfunction-Associated Steatotic Liver Disease, Non-alcoholic Fatty Liver Disease
Alternate Dosing Study of MK-6024 in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) (MK-6024-016)
This study will evaluate the effect of efinopegdutide administration once every 2 weeks (Q2W) versus once weekly (Q1W) on mean relative reduction from baseline in liver fat content (LFC) after 28 weeks, as well as the safety and…
- Conditions
- Metabolic Dysfunction-Associated Steatotic Liver Disease, Non-alcoholic Fatty Liver Disease, Nonalcoholic Fatty Liver Disease, Liver Disease
- Trial name
- NCT06482112
- Testing
- Efinopegdutide
- Where
- 39 sites in United States, Puerto Rico
- Volunteers
- 124 people
- Sponsor
- Merck Sharp & Dohme LLC
Non-alcoholic Fatty Liver Disease (NAFLD)
Elucidating Hepatic Metabolism in Non-alcoholic Fatty Liver Disease
The goal of this observational, cross-sectional, case-control clinical study is to investigate the metabolic adaptations underlying the progression of nonalcoholic fatty liver disease (NAFLD), and to test the hypothesis that…
- Trial name
- ECHO (NCT06942312)
- Testing
- Ketoisocaproic acid breath test, Ammonium Chloride, Bicarbonate de sodium
- Where
- Finland
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Helsinki University Central Hospital
Fatty Liver
Insulin Resistance in Non-alcoholic Fatty Liver Disease
The study is designed to investigate the relationship between insulin resistance and non-alcoholic fatty liver disease (NAFLD) and to investigate potential mechanisms underlying insulin resistance in NAFLD by determining…
- Trial name
- NCT01289639
- Testing
- fenofibrate, pioglitazone
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Non-Alcoholic Fatty Liver Disease, Fecal Microbiota Transplantation
Impact of FMT on the Phenome in Patients With NAFLD and Fibrosis
The goal of this pilot experimental medicine interventional study is to explore the degree of transferability of the gut microbiome and associated metabolomic changes in patients with non-alcoholic fatty liver disease (NAFLD) and…
- Trial name
- NCT06024681
- Testing
- Faecal microbiota transplant
- Where
- United Kingdom
- Volunteers
- 16 people
- Sponsor
- Imperial College London
Lysosomal Acid Lipase Deficiency
Clinical Study In Infants With Rapidly Progressive Lysosomal Acid Lipase Deficiency
This was an open-label, repeat-dose, study of sebelipase alfa in infants with rapidly progressive lysosomal acid lipase deficiency (LAL-D). Eligible participants received once-weekly infusions of sebelipase alfa for up to 3 years.
- Trial name
- NCT02193867
- Testing
- Sebelipase Alfa
- Where
- 5 sites in United States, Finland and 2 more
- Volunteers
- 10 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
Non-Alcoholic Fatty Liver Disease
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BAR 502 in Healthy Subjects
This is a prospective, single-center, randomized, double-blind, placebo-controlled, single-ascending dose (SAD) phase 1 study to evaluate the safety and tolerability of single-ascending doses of BAR 502 in healthy male and female…
- Trial name
- NCT05203367
- Testing
- BAR502
- Where
- Portugal
- Volunteers
- healthy volunteers welcome
- Sponsor
- BAR Pharmaceuticals s.r.l.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.